These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 28197794)

  • 1. Therapeutic Options in Refractory Diabetic Macular Oedema.
    Shah SU; Maturi RK
    Drugs; 2017 Apr; 77(5):481-492. PubMed ID: 28197794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rho-Kinase Inhibitors for the Treatment of Refractory Diabetic Macular Oedema.
    Mateos-Olivares M; García-Onrubia L; Valentín-Bravo FJ; González-Sarmiento R; Lopez-Galvez M; Pastor JC; Usategui-Martín R; Pastor-Idoate S
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of vascular endothelial growth factor inhibitors and laser therapy for diabetic macular oedema: a review.
    Mehta H; Gillies MC; Fraser-Bell S
    Clin Exp Ophthalmol; 2016 May; 44(4):335-9. PubMed ID: 27061760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group.
    Amoaku WM; Ghanchi F; Bailey C; Banerjee S; Banerjee S; Downey L; Gale R; Hamilton R; Khunti K; Posner E; Quhill F; Robinson S; Setty R; Sim D; Varma D; Mehta H
    Eye (Lond); 2020 Jun; 34(Suppl 1):1-51. PubMed ID: 32504038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intravitreal dexamethasone implant on retinal and choroidal thickness in refractory diabetic macular oedema after multiple anti-VEGF injections.
    Kim M; Cho YJ; Lee CH; Lee SC
    Eye (Lond); 2016 May; 30(5):718-25. PubMed ID: 26939558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
    Parravano M; Menchini F; Virgili G
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007419. PubMed ID: 19821414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic macular oedema: pathophysiology, management challenges and treatment resistance.
    Bahrami B; Zhu M; Hong T; Chang A
    Diabetologia; 2016 Aug; 59(8):1594-608. PubMed ID: 27179659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema.
    Wong Y; Steel DHW; Habib MS; Stubbing-Moore A; Bajwa D; Avery PJ;
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):733-742. PubMed ID: 27957600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Six-month changes in cytokine levels after intravitreal bevacizumab injection for diabetic macular oedema and macular oedema due to central retinal vein occlusion.
    Wen J; Jiang Y; Zheng X; Zhou Y
    Br J Ophthalmol; 2015 Oct; 99(10):1334-40. PubMed ID: 25841235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy.
    Mikhail M; Stewart S; Seow F; Hogg R; Lois N
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1411-1418. PubMed ID: 29779188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of baseline diabetic retinopathy status on initial anatomical response of intravitreal ranibizumab therapy for diabetic macular oedema.
    Nicholson L; Patrao NV; Ramu J; Vazquez-Alfageme C; Muwas M; Rajendram R; Hykin PG; Sivaprasad S
    Eye (Lond); 2017 Sep; 31(9):1358-1364. PubMed ID: 28452992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years.
    Fusi-Rubiano W; Mukherjee C; Lane M; Tsaloumas MD; Glover N; Kidess A; Denniston AK; Palmer HE; Manna A; Morjaria R
    BMC Ophthalmol; 2018 Feb; 18(1):62. PubMed ID: 29486754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of therapies for diabetic macular oedema and rationale for combination therapy.
    Amoaku WM; Saker S; Stewart EA
    Eye (Lond); 2015 Sep; 29(9):1115-30. PubMed ID: 26113500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review.
    Massa H; Nagar AM; Vergados A; Dadoukis P; Patra S; Panos GD
    J Int Med Res; 2019 Jan; 47(1):31-43. PubMed ID: 30556449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic factors for visual outcome after intravitreal drug therapy for chronic diabetic macular oedema].
    Guthoff R; Schrader W; Hennemann K; Meigen T; Göbel W
    Klin Monbl Augenheilkd; 2011 May; 228(5):468-72. PubMed ID: 20597042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.
    Fang X; Sakaguchi H; Gomi F; Oshima Y; Sawa M; Tsujikawa M; Ikuno Y; Kamei M; Kusaka S; Tano Y
    Acta Ophthalmol; 2008 Nov; 86(7):800-5. PubMed ID: 18547274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-vascular endothelial growth factor agents for diabetic maculopathy.
    Salam A; DaCosta J; Sivaprasad S
    Br J Ophthalmol; 2010 Jul; 94(7):821-6. PubMed ID: 19556214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic macular oedema in 2011: what are the options for refractory cystic oedema?
    Wickremasinghe S
    Clin Exp Ophthalmol; 2011; 39(7):595-7. PubMed ID: 22452678
    [No Abstract]   [Full Text] [Related]  

  • 19. A randomized clinical trial comparing fixed vs pro-re-nata dosing of Ozurdex in refractory diabetic macular oedema (OZDRY study).
    Ramu J; Yang Y; Menon G; Bailey C; Narendran N; Bunce C; Quartilho A; Prevost AT; Hykin P; Sivaprasad S;
    Eye (Lond); 2015 Dec; 29(12):1603-12. PubMed ID: 26493038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classification of diabetic macular oedema using ultra-widefield angiography and implications for response to anti-VEGF therapy.
    Xue K; Yang E; Chong NV
    Br J Ophthalmol; 2017 May; 101(5):559-563. PubMed ID: 27531355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.